| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
123,030,000 |
| Market
Cap: |
18.60(B) |
| Last
Volume: |
934,860 |
Avg
Vol: |
724,527 |
| 52
Week Range: |
$143.31 - $211.65 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 824 |
| Guru Rank Value : 0.5 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapeutics based on RNA interference. Co. has four RNAi-based medicines, ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO™ (lumasiran) and Leqvio® (inclisiran). ONPATTRO is approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. GIVLAARI is approved for the treatment of adults with acute hepatic porphyria. Co. has approval for OXLUMO for the treatment of hyperoxaluria type 1 (PH1) in all age groups. Leqvio (inclisiran) is being developed for the treatment of adults with hypercholesterolemia or mixed dyslipidemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
45,264 |
76,855 |
102,504 |
247,093 |
| Total Sell Value |
$6,835,665 |
$12,957,715 |
$17,713,340 |
$48,829,179 |
| Total People Sold |
6 |
7 |
8 |
9 |
| Total Sell Transactions |
10 |
12 |
18 |
35 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Keating Laurie |
SVP, GC & Secretary |
• – – |
2018-06-20 |
4 |
AS |
$105.04 |
$164,178 |
D/D |
(1,563) |
14,500 |
|
- |
|
| Keating Laurie |
SVP, GC & Secretary |
• – – |
2018-06-20 |
4 |
OE |
$42.22 |
$65,990 |
D/D |
1,563 |
16,063 |
|
- |
|
| Clarke John K |
Director |
– • – |
2018-05-31 |
4 |
AS |
$99.38 |
$1,504,678 |
D/D |
(15,000) |
8,891 |
|
- |
|
| Clarke John K |
Director |
– • – |
2018-05-31 |
4 |
OE |
$27.28 |
$409,200 |
D/D |
15,000 |
23,891 |
|
- |
|
| Greene Barry E |
President |
• – – |
2018-04-16 |
4 |
A |
$0.00 |
$0 |
I/I |
28 |
2,855 |
|
- |
|
| Soni Manmeet Singh |
Chief Financial Officer |
• – – |
2018-04-16 |
4 |
A |
$0.00 |
$0 |
I/I |
28 |
47 |
|
- |
|
| Vaishnaw Akshay |
President, R&D |
• – – |
2018-04-16 |
4 |
A |
$0.00 |
$0 |
I/I |
28 |
366 |
|
- |
|
| Mason Michael |
VP, Finance and Treasurer |
• – – |
2018-04-16 |
4 |
A |
$0.00 |
$0 |
I/I |
22 |
253 |
|
- |
|
| Greenstreet Yvonne |
EVP, Chief Operating Officer |
• – – |
2018-04-16 |
4 |
A |
$0.00 |
$0 |
I/I |
37 |
270 |
|
- |
|
| Maraganore John |
Chief Executive Officer |
• • – |
2018-04-16 |
4 |
A |
$0.00 |
$0 |
I/I |
30 |
2,990 |
|
- |
|
| Keating Laurie |
SVP, GC & Secretary |
• – – |
2018-04-16 |
4 |
A |
$0.00 |
$0 |
I/I |
31 |
288 |
|
- |
|
| Greenstreet Yvonne |
EVP, Chief Operating Officer |
• – – |
2018-03-26 |
4 |
A |
$0.00 |
$0 |
I/I |
233 |
233 |
|
- |
|
| Greenstreet Yvonne |
EVP, Chief Operating Officer |
• – – |
2018-03-26 |
4 |
AS |
$136.00 |
$985,958 |
D/D |
(7,221) |
0 |
|
- |
|
| Greenstreet Yvonne |
EVP, Chief Operating Officer |
• – – |
2018-03-26 |
4 |
OE |
$42.22 |
$304,871 |
D/D |
7,221 |
7,221 |
|
- |
|
| Keating Laurie |
SVP, GC & Secretary |
• – – |
2018-03-20 |
4 |
AS |
$146.36 |
$234,033 |
D/D |
(1,562) |
14,500 |
|
- |
|
| Keating Laurie |
SVP, GC & Secretary |
• – – |
2018-03-20 |
4 |
OE |
$42.22 |
$65,948 |
D/D |
1,562 |
16,062 |
|
- |
|
| Greene Barry E |
President |
• – – |
2018-03-14 |
4 |
AS |
$140.43 |
$5,503,736 |
D/D |
(38,460) |
61,968 |
|
- |
|
| Vaishnaw Akshay |
President, R&D |
• – – |
2018-03-14 |
4 |
AS |
$140.45 |
$12,672,126 |
D/D |
(88,554) |
11,215 |
|
- |
|
| Vaishnaw Akshay |
President, R&D |
• – – |
2018-03-14 |
4 |
OE |
$7.10 |
$1,507,842 |
D/D |
88,554 |
99,769 |
|
- |
|
| Ausiello Dennis A |
Director |
– • – |
2018-03-13 |
4 |
AS |
$150.00 |
$2,567,550 |
D/D |
(17,117) |
0 |
|
- |
|
| Ausiello Dennis A |
Director |
– • – |
2018-03-13 |
4 |
OE |
$59.25 |
$1,023,942 |
D/D |
17,117 |
17,117 |
|
- |
|
| Schimmel Paul |
Director |
– • – |
2018-03-13 |
4 |
AS |
$150.00 |
$4,173,450 |
D/D |
(27,823) |
0 |
|
- |
|
| Schimmel Paul |
Director |
– • – |
2018-03-13 |
4 |
OE |
$30.09 |
$1,369,927 |
D/D |
27,823 |
27,823 |
|
- |
|
| Sharp Philip A |
Director |
– • – |
2018-03-13 |
4 |
AS |
$149.00 |
$2,235,000 |
D/D |
(15,000) |
140,795 |
|
- |
|
| Sharp Philip A |
Director |
– • – |
2018-03-13 |
4 |
OE |
$21.35 |
$320,250 |
D/D |
15,000 |
155,795 |
|
- |
|
746 Records found
|
|
Page 12 of 30 |
|
|
3.82 (2.59%) 
